News | Medical Marketing & Media | MM&M

News

HBA adds 10 to its board.

The Healthcare Businesswomen’s Association (HBA) has appointed an additional 10 new members to its 25-member advisory board. Many of the new members are recipients of the HBA’s annual Woman of the Year or Honorable Mentor awards.

Novartis receives supplemental indication for pro-motility agent Zelnorm

Novartis reported that the FDA has approved a supplemental indication for its pro-motility agent Zelnorm for the treatment of chronic idiopathic constipation in male and female patients less than 65 years of age. The new indication is supported by safety and efficacy data from the two largest and longest mrandomized, double-blind, placebo-controlled, multi-national Phase III…

Low-dose version of Prempro approved

The FDA approved a low-dose version of Wyeth Pharmaceuticals‘ hormone replacement therapy Prempro (conjugated estrogens and medroxyprogesterone). The low-dose Prempro has 28 percent less estrogen and 40 percent less progestin than full-dose Prempro, Wyeth reported. It contains 0.45 mg of conjugated estrogens and 1.5 mg of medroxyprogesterone. This version is indicated for use in the…

Light Sciences announce approval for Japanese licensor

Seattle-based Light Sciences reported that Meiji Seika, the licensor of its lead compound, LS11 (Laserphyrin in Japan), received a recommendation for approval by Pharmaceutical Affairs and Food Sanitation Council of the Ministry of Health, Labor and Welfare in Japan. The approval will be granted for the photodynamic treatment of early endobronchial carcinoma. The Japanese regulatory…

Kos Pharmaceuticals and Takeda Pharmaceuticals reach agreement to co-promote Niaspan and Advicor

Kos Pharmaceuticals and Takeda Pharmaceuticals have reached a three-year agreement to co-promote Kos’ Niaspan and Advicor in the U.S. market. The agreement adds more than 1,000 Takeda sales representatives to the existing Kos sales force to detailthe two products developed by Kos for treating cholesterol disorders. Theincreased promotional effort is expected to significantly enhance the…

FDA approves new scent-free formulation of Nasonex

Schering-Plough reported that the FDA has approved a new scent-free formulation of Nasonex prescription nasal inhaled steroid. Nasonex remains the first and only once-daily prescription nasal inhaled steroid approved to help prevent most seasonal nasal allergy symptoms, including nasal congestion, in adults and children 12 years of age and older and the only nasal inhaled…

Enjuvia gets U.S. regulatory approval

Barr Pharmaceuticals received U.S. regulatory approval for a new female hormone replacement
product called Enjuvia. The plant-derived product was approved by the FDA for the treatment
of moderate to severe vasomotor symptoms associated with menopause.

Wyeth launches new Prempro ads

Healthworld Communications, New York, has created a new ad campaign for Wyeth’s Prempro that includes
a 60-second television spot and a consumer print ad. The ads begin running this month. The 60-second spot will air on network programs such as Entertainment Tonight and CSI: Miami.